← All trials
NCT01442935
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2011
- Primary completion
- Nov 1, 2016
- Completion date
- Feb 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 256
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- UNICANCERLead sponsor
- University of ReimsOverall official - principal investigator
- Centre Val d'AurelleOverall official - principal investigator
- Centre hospitalier PurpanOverall official - principal investigator
- University of BordeauxOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
- University of LyonOverall official - principal investigator
- Saint-Joseph UniversityOverall official - principal investigator
- Curie InstituteOverall official - principal investigator
- Institut Sainte CatherineOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.